GlobalData on MSN14h
Big pharma faces headwinds in China as vaccine sales declineMultinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.
Read more on 2 durable dividend stocks that offer higher yields and strong cash flows, outperforming the S&P 500 in value, ...
The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis and Novo fine tuned its Wegovy cash-pay program.
The company plans to file next year for an accelerated clearance of its "exon-skipping" treatment, which would compete with one of Sarepta's medicines.
Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.
The Business Research Company The Business Research Company's Myocarditis Disease Global Market Report 2025 – Market Size, Trends, And Glob ...
Trump's proposed tariffs on the EU would increase manufacturing costs for pharma companies and would stall medical innovation ...
Democratic nominee for U.S. President, Kamala Harris spent a lot of time talking about the middle class, but her own net ...
Intelligence Officials Are Grilled After More Signal Texts Are Released The national intelligence director and the C.I.A. chief, both of whom were in the Signal chat, faced lawmakers in the House ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback